Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Athyros, Vasilios G [Clear All Filters]
Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases..
Open Cardiovasc Med J. 5, 85-9.
(2011). Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?.
Curr Vasc Pharmacol. 9(6), 698-705.
(2011). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011). IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011). Residual cardiac risk reduction beyond lipid lowering..
Hellenic J Cardiol. 52(3), 197-203.
(2011).
(2011). Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?.
Curr Opin Cardiol. 25(4), 406-10.
(2010). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population..
Curr Med Res Opin. 26(3), 713-9.
(2010). Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?.
Curr Vasc Pharmacol. 8(1), 1-4.
(2010). The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis..
Curr Vasc Pharmacol. 8(6), 792-803.
(2010). Effect of antihypertensive drug-associated diabetes on cardiovascular risk..
Hellenic J Cardiol. 51(3), 195-9.
(2010). Endocrine hypertension: diagnosis and management of a complex clinical entity..
Curr Vasc Pharmacol. 8(5), 646-60.
(2010). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy..
Expert Opin Pharmacother. 11(5), 723-30.
(2010). Lipid-lowering agents and new onset diabetes mellitus..
Expert Opin Pharmacother. 11(12), 1965-70.
(2010). Management of statin-intolerant high-risk patients..
Curr Vasc Pharmacol. 8(5), 632-7.
(2010). Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?.
Curr Pharm Des. 16(34), 3939-847.
(2010). The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification..
Curr Opin Cardiol. 25(4), 394-8.
(2010). Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis..
Lancet. 376(9756), 1916-22.
(2010). Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients..
Neurol Res. 32(3), 326-31.
(2010). Should adipokines be considered in the choice of the treatment of obesity-related health problems?.
Curr Drug Targets. 11(1), 122-35.
(2010). Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?.
Curr Med Res Opin. 26(4), 839-42.
(2010). Statin-fibrate combination for mixed dyslipidaemia: a limited option?.
Curr Med Res Opin. 26(9), 2137-40.
(2010). Statins and heart failure..
J Am Coll Cardiol. 55(15), 1644-5; author reply 1646.
(2010).